{
    "analytics_identifier":  null,
    "base_path":  "/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
    "content_id":  "5f5ea58c-7631-11e4-a3cb-005056011aef",
    "description":  "How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application. ",
    "details":  {
                    "attachments":  [
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  69587,
                                            "filename":  "Algorithm_Clean__1_.pdf",
                                            "id":  "8251437",
                                            "number_of_pages":  2,
                                            "title":  "Is it a clinical trial of a medicinal product?",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5fef0e5ee90e0776aeac5797/Algorithm_Clean__1_.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  26549,
                                            "filename":  "CTA_MOCK_Examples.pdf",
                                            "id":  "8251438",
                                            "number_of_pages":  6,
                                            "title":  "clinical trial mock examples",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a81dee540f0b62305b91402/CTA_MOCK_Examples.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  21575,
                                            "filename":  "PET_ligand_trials.pdf",
                                            "id":  "8251439",
                                            "number_of_pages":  5,
                                            "title":  "PET ligand trials",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7df66fed915d74e622334e/PET_ligand_trials.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  4258129,
                                            "filename":  "Over-encapsulation_of_a_tablet.pdf",
                                            "id":  "8251440",
                                            "number_of_pages":  5,
                                            "title":  "Over-encapsulation of a tablet",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7e42e6ed915d74e33f11b3/Over-encapsulation_of_a_tablet.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  261036,
                                            "filename":  "Over-encapsulation_of_a_broken_tablet.pdf",
                                            "id":  "8251441",
                                            "number_of_pages":  5,
                                            "title":  "Over-encapsulation of a broken tablet",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7d7390ed915d2d2ac09098/Over-encapsulation_of_a_broken_tablet.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  4262689,
                                            "filename":  "Drug_substance_powder_filled_into_capsules.pdf",
                                            "id":  "8251442",
                                            "number_of_pages":  4,
                                            "title":  "Drug substance powder filled into capsules",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7dbe8ee5274a5eaea66128/Drug_substance_powder_filled_into_capsules.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  4336223,
                                            "filename":  "Mock_IMPD_for_PET___non_clinical.pdf",
                                            "id":  "8251443",
                                            "number_of_pages":  7,
                                            "title":  "Mock IMPD for PET – non clinical",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7dce4eed915d2ac884daa8/Mock_IMPD_for_PET___non_clinical.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  4399755,
                                            "filename":  "Mock_IMPD_for_PET_-_pharmaceutical.pdf",
                                            "id":  "8251444",
                                            "number_of_pages":  14,
                                            "title":  "Mock IMPD for PET - pharmaceutical",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7da2ece5274a6b89a513d1/Mock_IMPD_for_PET_-_pharmaceutical.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  56115,
                                            "filename":  "Points_to_consider_when_preparing_the_IMP_dossier.pdf",
                                            "id":  "8251445",
                                            "number_of_pages":  3,
                                            "title":  "Points to consider when preparing the IMP dossier",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7d7a4ae5274a676d5324d8/Points_to_consider_when_preparing_the_IMP_dossier.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  22501,
                                            "filename":  "Common_errors_seen_at_validation.pdf",
                                            "id":  "8251446",
                                            "number_of_pages":  1,
                                            "title":  "common errors seen at validation",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5aa69ac8ed915d4f563b6eec/Common_errors_seen_at_validation.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  54133,
                                            "filename":  "Guidance_on_preparing_PDF_documents.pdf",
                                            "id":  "8251447",
                                            "number_of_pages":  2,
                                            "title":  "guidance on applications requiring expert advice ",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7d849940f0b64a5813f7cb/Guidance_on_preparing_PDF_documents.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  49877,
                                            "filename":  "Guidance_for_rejection_applications.pdf",
                                            "id":  "8251448",
                                            "number_of_pages":  2,
                                            "title":  "Guidance for applications where grounds for non-acceptance have been raised",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7e3539e5274a2e8ab4689a/Guidance_for_rejection_applications.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  59695,
                                            "filename":  "Making_an_application_under_the_notification_scheme.pdf",
                                            "id":  "8251449",
                                            "number_of_pages":  3,
                                            "title":  "Making an application under the notification scheme",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7d7262e5274a7b50ccf062/Making_an_application_under_the_notification_scheme.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  4683157,
                                            "filename":  "Risk-adapted_approaches_to_the_management_of_clinical_trials_of_investigational_medicinal_products.pdf",
                                            "id":  "8251450",
                                            "number_of_pages":  31,
                                            "title":  "risk-adapted approaches to the management of clinical trials of investigational medicinal products",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5a7dfcf6e5274a2e87daecfd/Risk-adapted_approaches_to_the_management_of_clinical_trials_of_investigational_medicinal_products.pdf"
                                        },
                                        {
                                            "accessible":  true,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  16260,
                                            "filename":  "Points_to_consider_for_trials_allowing_inclusion_of_patients_previously_treated_with_an_Advanced_Therapy_Medicinal_Product_Web.pdf",
                                            "id":  "8251451",
                                            "number_of_pages":  3,
                                            "title":  "Points to consider for trials allowing inclusion of patients previously treated with an Advanced Therapy Medicinal Product",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5b7e88fced915d14eb0e3207/Points_to_consider_for_trials_allowing_inclusion_of_patients_previously_treated_with_an_Advanced_Therapy_Medicinal_Product_Web.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/vnd.openxmlformats-officedocument.wordprocessingml.document",
                                            "file_size":  237533,
                                            "filename":  "Scope_-_request_form.docx",
                                            "id":  "8251452",
                                            "title":  "request for an opinion on whether a study is a clinical trial of an investigational medicinal product under The Medicines for Human Use (Clinical Trials) Regulations 2004",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5fef0f07e90e07769f7d88e2/Scope_-_request_form.docx"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  241331,
                                            "filename":  "Mock_examples_to_assist_with_determination_of_a_CTIMP.pdf",
                                            "id":  "8251453",
                                            "number_of_pages":  9,
                                            "title":  "Mock examples to assist with determination of a CTIMP",
                                            "url":  "https://assets.publishing.service.gov.uk/media/6155a0e88fa8f52986e61b8b/Mock_examples_to_assist_with_determination_of_a_CTIMP.pdf"
                                        },
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/vnd.openxmlformats-officedocument.wordprocessingml.document",
                                            "file_size":  50900,
                                            "filename":  "Tabular_Summary_input__template__for_non_marked_IVD_devices.docx",
                                            "id":  "8251454",
                                            "title":  "Tabular Summary",
                                            "url":  "https://assets.publishing.service.gov.uk/media/657b0748095987001295e0f4/Tabular_Summary_input__template__for_non_marked_IVD_devices.docx"
                                        },
                                        {
                                            "accessible":  true,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/vnd.openxmlformats-officedocument.wordprocessingml.document",
                                            "file_size":  28273,
                                            "filename":  "Combined_IMP_Device_guidance_10.04.2024.docx",
                                            "id":  "8251455",
                                            "title":  "Combined IMP Device Guidance",
                                            "url":  "https://assets.publishing.service.gov.uk/media/66167bd16ad004cd0fac0580/Combined_IMP_Device_guidance_10.04.2024.docx"
                                        }
                                    ],
                    "body":  "\u003cdiv class=\"govspeak\"\u003e\u003cdiv class=\"call-to-action\"\u003e\n  \u003cp\u003e\u003cstrong\u003eNew Notification Scheme\u003c/strong\u003e\u003c/p\u003e\n\n  \u003cp\u003eWe have launched our new Notification Scheme that enables a more streamlined and risk-proportionate approach to processing Clinical Trial Authorisations (\u003cabbr title=\"clinical trial authorisation\"\u003eCTA\u003c/abbr\u003e) for “initial” applications in Phase 3 and 4 trials.\u003c/p\u003e\n\n  \u003cp\u003e\u003ca href=\"#new-notification-scheme\" class=\"govuk-link\"\u003eRead more and register your interest\u003c/a\u003e.\u003c/p\u003e\n\u003c/div\u003e\n\n\u003cdiv class=\"call-to-action\"\u003e\n  \u003cp\u003eAs of 1 January 2022 the combined review service, (formerly known as Combined Ways of Working (CWoW), is the way that all new Clinical Trials of Investigational Medicinal Products (CTIMPs) applications are prepared, submitted and reviewed. Combined review offers a single application route and co-ordinated review leading to a single UK decision for CTIMPs.\u003c/p\u003e\n\n  \u003cp\u003ePlease note: CTIMP applications via combined review should be started and submitted using the new part of Integrated Research Application System (\u003ca rel=\"external\" href=\"http://www.myresearchproject.org.uk/CWOW\" class=\"govuk-link\"\u003eIRAS\u003c/a\u003e) and not in the standard part of IRAS.  While the regulatory requirements and fees remain the same, the application submission, processing and assessment steps outlined below refer to non-combined review applications. For Combined review applications please refer to the \u003ca rel=\"external\" href=\"https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/clinical-trials-investigational-medicinal-products-ctimps/combined-ways-working-pilot/\" class=\"govuk-link\"\u003eHealth Research Authority website\u003c/a\u003e.\u003c/p\u003e\n\u003c/div\u003e\n\n\u003cdiv class=\"call-to-action\"\u003e\n  \u003ch2 id=\"clinical-trials-and-coronavirus-covid-19\"\u003eClinical Trials and coronavirus (COVID-19)\u003c/h2\u003e\n  \u003cp\u003eWe have published guidance on \u003ca href=\"https://www.gov.uk/guidance/managing-clinical-trials-during-coronavirus-covid-19\" class=\"govuk-link\"\u003emanaging clinical trials\u003c/a\u003e during the COVID-19 outbreak, and on \u003ca href=\"https://www.gov.uk/guidance/clinical-trials-applications-for-coronavirus-covid-19\" class=\"govuk-link\"\u003eclinical trials applications for COVID-19\u003c/a\u003e.\u003c/p\u003e\n\u003c/div\u003e\n\n\u003ch2 id=\"when-a-clinical-trial-authorisation-cta-is-needed\"\u003eWhen a clinical trial authorisation (\u003cabbr title=\"clinical trial authorisation\"\u003eCTA\u003c/abbr\u003e) is needed\u003c/h2\u003e\n\n\u003cp\u003eUse the online algorithm \u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/949145/Algorithm_Clean__1_.pdf\" class=\"govuk-link\"\u003eIs it a clinical trial of a medicinal product?\u003c/a\u003e (PDF, 68KB, 2 pages) to find out if your study needs MHRA authorisation.\u003c/p\u003e\n\n\u003cp\u003eThe algorithm is a set of questions that determine:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ewhether the substance you’re testing counts as a medicinal product\u003c/li\u003e\n  \u003cli\u003ewhether your trial counts as a clinical trial within the scope of the relevant legislation\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eYou can also read the \u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1022203/Mock_examples_to_assist_with_determination_of_a_CTIMP.pdf\" class=\"govuk-link\"\u003eMock examples to assist with the question ‘Is it a clinical trial of an investigational medicinal product?’\u003c/a\u003e to help you decide if your study needs a \u003cabbr title=\"clinical trial authorisation\"\u003eCTA\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003eFor further advice you may also wish to consult your local regulatory department or research governance team.\nFrom October 2021 the ‘SCOPE’ advice service will only be available via self-service using the guidance on this webpage.\u003c/p\u003e\n\n\u003ch3 id=\"please-note\"\u003ePlease note\u003c/h3\u003e\n\n\u003cp\u003eThis guidance relates to clinical trials of medicinal products. If your query relates to a clinical investigation of a medical device please contact \u003ca href=\"mailto:info@mhra.gov.uk\" class=\"govuk-link\"\u003einfo@mhra.gov.uk\u003c/a\u003e.\u003c/p\u003e\n\n\u003cp\u003eTo get advice on whether a trial is a Type A, B or C based on risk assessment please view our guidance on \u003ca href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/343677/Risk-adapted_approaches_to_the_management_of_clinical_trials_of_investigational_medicinal_products.pdf\" class=\"govuk-link\"\u003erisk-adapted approaches to the management of clinical trials of investigational medicinal products\u003c/a\u003e. Should you have a query regarding any proposed risk adaptations please send an email with your query to \u003ca href=\"mailto:clintrialhelpline@mhra.gov.uk\" class=\"govuk-link\"\u003eclintrialhelpline@mhra.gov.uk\u003c/a\u003e.\u003c/p\u003e\n\n\u003cp\u003eIf your query relates to whether the study product(s) is/are an Investigational Medicinal Product (IMP) or non-IMP, please consult the document \u003ca rel=\"external\" href=\"https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-10/imp_03-2011.pdf\" class=\"govuk-link\"\u003e‘Guidance on investigational medicinal products (IMPs) and ‘non investigational medicinal products’ (NIMPS) (Rev. 1, March 2011)’\u003c/a\u003e .\u003c/p\u003e\n\n\u003cp\u003eIf you wish to know whether your product could be a medicine, rather than a medical device or other product (such as a food supplement or cosmetic), please refer to the \u003ca href=\"https://www.gov.uk/guidance/borderline-products-how-to-tell-if-your-product-is-a-medicine\" class=\"govuk-link\"\u003emedicines borderline page\u003c/a\u003e.\u003c/p\u003e\n\n\u003ch2 id=\"trial-sponsor-and-legal-representative\"\u003eTrial Sponsor and legal Representative\u003c/h2\u003e\n\n\u003cp\u003eThe sponsor of a clinical trial is the person who takes responsibility for the initiation, management and financing (or arranging the financing) of that trial. Clinical trials can also be sponsored by two or more persons or organisations. This is referred to as joint or co-sponsorship. Regulation 3 (2) of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031) provides further information on the responsibilities of the sponsor(s).\u003c/p\u003e\n\n\u003cp\u003eA sponsor of a clinical trial needs to be established in the UK or a country on an \u003ca href=\"https://www.gov.uk/government/publications/importing-investigational-medicinal-products-into-great-britain-from-approved-countries\" class=\"govuk-link\"\u003eapproved country list\u003c/a\u003e which would initially include EU/European Economic Area (EEA) countries. If this is not the case, then the sponsor must have a legal representative who is so established.\u003c/p\u003e\n\n\u003ch2 id=\"registration-of-your-clinical-trial\"\u003eRegistration of your clinical trial\u003c/h2\u003e\n\n\u003cp\u003eFrom 1 January 2022 the Health Research Authority (HRA) will automatically register clinical trials with ISRCTN Registry as one of the steps to ensure research transparency. This will start with clinical trials of investigational medicinal products (CTIMPs) that are submitted through combined review in the new part of IRAS. It is still a standard condition of a Research Ethics Committee (\u003cabbr title=\"Research Ethics Committee\"\u003eREC\u003c/abbr\u003e) favourable opinion for clinical trials to be registered on a publicly accessible database, this requirement has not changed. For any submissions submitted up to 31 December 2021 (either via new IRAS or old IRAS) you should register your clinical trials on an established international register such as ISRCTN Registry or ClinicalTrials.gov. If you wish to defer registration of your trial (for example if it is an adult phase I trial) then contact the HRA at \u003ca href=\"mailto:study.registration@hra.nhs.uk\" class=\"govuk-link\"\u003estudy.registration@hra.nhs.uk\u003c/a\u003e.\u003c/p\u003e\n\n\u003cp\u003eYou should continue to include the registry number(s), if available, in section A.5. of the application form in the Integrated Research Application System (IRAS) when you prepare your application. If this is not available at the time of application, you should email this to the MHRA at \u003ca href=\"mailto:clintrialhelpline@mhra.gov.uk\" class=\"govuk-link\"\u003eclintrialhelpline@mhra.gov.uk\u003c/a\u003e with subject line “Clinical Trial Registration” within six weeks of recruiting the first research participant. You should also let the \u003ca rel=\"external\" href=\"https://www.hra.nhs.uk/about-us/committees-and-services/res-and-recs/search-research-ethics-committees/\" class=\"govuk-link\"\u003e\u003cabbr title=\"Research Ethics Committee\"\u003eREC\u003c/abbr\u003e\u003c/a\u003e know your registration number as soon as possible.\u003c/p\u003e\n\n\u003ch2 id=\"combined-review-of-clinical-trials-of-investigational-medicinal-products\"\u003eCombined review of clinical trials of investigational medicinal products\u003c/h2\u003e\n\n\u003cp\u003eFrom 1 January 2022, all new Clinical Trials of Investigational Medicinal Products (CTIMPs) applications will be prepared, submitted and reviewed via the combined review service. This offers CTIMP applicants and sponsors a single application route and co-ordinated review by MHRA and the research ethics committee, leading to a single UK decision.\u003c/p\u003e\n\n\u003cp\u003eApplications for combined review are prepared and submitted in a new part of the \u003ca rel=\"external\" href=\"https://www.myresearchproject.org.uk/CWOW\" class=\"govuk-link\"\u003eIntegrated Research Application System\u003c/a\u003e (IRAS). Further information on the process is available via the \u003ca rel=\"external\" href=\"https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/clinical-trials-investigational-medicinal-products-ctimps/combined-ways-working-pilot/#contents\" class=\"govuk-link\"\u003eHealth research Authority website\u003c/a\u003e.\u003c/p\u003e\n\n\u003ch2 id=\"combined-review-of-a-ctimp-and-medical-device\"\u003eCombined review of a CTIMP and Medical Device\u003c/h2\u003e\n\n\u003cp\u003eCombined review is the way research teams seek approval for new Clinical Trials of Investigational Medicinal Products (CTIMPs) and combined medicine and device trials.\u003c/p\u003e\n\n\u003cp\u003eResearch teams make a single application using a new part of IRAS, which goes to both the Medicines and Healthcare products Regulatory Agency (MHRA) and a research ethics committee (\u003cabbr title=\"Research Ethics Committee\"\u003eREC\u003c/abbr\u003e) at the same time. The application also goes for study wide review, such as HRA and HCRW approval, if the study is to take place in the NHS or Northern Ireland HSC.\u003c/p\u003e\n\n\u003cp\u003eThe regulatory and ethics reviews are done in parallel and any requests for further information (RFIs) are raised jointly. A single response to these requests leads to a single decision from both reviews. Study wide review is usually issued at the same time as MHRA and \u003cabbr title=\"Research Ethics Committee\"\u003eREC\u003c/abbr\u003e, but may come later if there are still issues to discuss with the applicant.\u003c/p\u003e\n\n\u003cp\u003eIRAS is used for the initial application and supports the trial through amendments right up to the end of the trial. Research teams can allocate different roles in the system for colleagues working on the project. Further information is available in our  \u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/media/66167bd16ad004cd0fac0580/Combined_IMP_Device_guidance_10.04.2024.docx\" class=\"govuk-link\"\u003eCombined IMP Device guidance\u003c/a\u003e\u003c/p\u003e\n\n\u003ch2 id=\"in-vitro-diagnostic-medical-devices-ivds\"\u003eIn Vitro Diagnostic Medical Devices (IVDs)\u003c/h2\u003e\n\n\u003cp\u003eUnless an exemption applies, all IVD devices being placed on the market or put into service in the UK are required to have the relevant mark of conformity (i.e. UKCA, CE or UKNI).\u003c/p\u003e\n\n\u003cp\u003eThis includes IVD devices used in clinical trials of medicines (CTIMPs) to stratify patients for inclusion/exclusion in the trial or stratified to a cohort within a trial.\u003c/p\u003e\n\n\u003cp\u003eAt the time of the clinical trial application, where clinical performance of the IVD device is yet to be demonstrated, for CTIMPs taking place in GB, the IVDs device must have demonstrated evidence supplied to the MHRA for the analytical performance of the IVD (e.g. detection of a biomarker) as summary reports of each study or protocol. This will include reagents, equipment, calibrators, controls and software. For use of IVD devices in CTIMPs conducted in Northern Ireland, refer to guidance available on \u003ca rel=\"external\" href=\"https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fguidance%2Fmedical-devices-eu-regulations-for-mdr-and-ivdr%23clinical-investigations-and-performance-studies-in-northern-ireland\u0026amp;data=05%7C02%7Cwebupdates%40mhra.gov.uk%7Ceeeb44bee763490cc48308dcc3584368%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638600031197055933%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C\u0026amp;sdata=Rt4jdykRHrDFcBK7HpIsON110K4k9vGHhDmuuX9O6zY%3D\u0026amp;reserved=0\" class=\"govuk-link\"\u003eClinical investigations and performance studies in Northern Ireland\u003c/a\u003e.\u003c/p\u003e\n\n\u003cp\u003eAlternatively, if the analytical performance study has not been conducted, the Sponsor must provide the MHRA with a \u003ca rel=\"external\" href=\"https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fassets.publishing.service.gov.uk%2Fmedia%2F657b0748095987001295e0f4%2FTabular_Summary_input__template__for_non_marked_IVD_devices.docx\u0026amp;data=05%7C02%7Cwebupdates%40mhra.gov.uk%7Ceeeb44bee763490cc48308dcc3584368%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638600031197063627%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C\u0026amp;sdata=HKwyRuoWOCktQ%2FPspkhLeeCJ8wGnTZT6DxyJyZb0liI%3D\u0026amp;reserved=0\" class=\"govuk-link\"\u003eTabular Summary\u003c/a\u003e (MS Word Document, 49.7 KB) description of the analytical methods including acceptance limits and parameters for performing validation. Please supply the contents requested without modifying the structure of the template.\u003c/p\u003e\n\n\u003cp\u003eTrials which determine the clinical performance of the assay will need to be \u003ca rel=\"external\" href=\"https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fguidance%2Fregister-medical-devices-to-place-on-the-market\u0026amp;data=05%7C02%7Cwebupdates%40mhra.gov.uk%7Ceeeb44bee763490cc48308dcc3584368%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638600031197073129%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C\u0026amp;sdata=hZO30wReQISzJTMWW3tITmNBX%2Bfw%2FX%2FW%2FjJZadbT%2FJ8%3D\u0026amp;reserved=0\" class=\"govuk-link\"\u003eregistered\u003c/a\u003e as IVD performance evaluation studies.\u003c/p\u003e\n\n\u003cp\u003eSee also \u003ca href=\"https://www.gov.uk/government/publications/in-vitro-diagnostic-medical-devices-guidance-on-legislation\" class=\"govuk-link\"\u003eguidance on in vitro diagnostic medical devices: guidance on legislation\u003c/a\u003e\u003c/p\u003e\n\n\u003ch2 id=\"documents-to-send-with-your-application\"\u003eDocuments to send with your application\u003c/h2\u003e\n\n\u003cp\u003eThe IRAS portal includes a list of documentation to submit for combined review of your application. The following provides some further guidance on the content of some of the specific MHRA documents:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ecovering letter: When applicable, the subject line should state that the submission is for a Phase I healthy volunteer trial and is eligible for a shortened assessment time, or if you are using risk proportionate approaches to the conduct of the study. Your covering letter should clearly highlight your Purchase Order (PO) number; this will help us to invoice and allocate your payments promptly and efficiently\u003c/li\u003e\n  \u003cli\u003einvestigational medical product dossier (IMPD): please note that an active substance master file (ASMF) is not acceptable as a substitute for an IMPD\u003c/li\u003e\n  \u003cli\u003emanufacturer’s authorisation, including the importer’s authorisation and Qualified Person declaration on \u003ca href=\"https://www.gov.uk/guidance/good-manufacturing-practice-and-good-distribution-practice\" class=\"govuk-link\"\u003egood manufacturing practice\u003c/a\u003e for each manufacturing site if the product is manufactured outside the EU. \u003ca href=\"https://www.gov.uk/government/publications/importing-investigational-medicinal-products-into-great-britain-from-approved-countries\" class=\"govuk-link\"\u003eFurther guidance covering this area\u003c/a\u003e.\u003c/li\u003e\n  \u003cli\u003econtent of the labelling of the investigational medicinal product (IMP): where this has not been provided please provide a justification for its absence\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eAll documents must have copy and paste functionality. We do not currently accept password-protected documents. Other published guidance remains relevant and should be consulted for further information on the submission requirements (with consideration of the MHRA as a sovereign regulator).\u003c/p\u003e\n\n\u003cp\u003eIf you are using an in vitro diagnostic device in your trial, the covering letter and/or protocol should confirm that any applicable \u003ca href=\"https://www.gov.uk/guidance/notify-mhra-about-a-clinical-investigation-for-a-medical-device#in-vitro-diagnostic-medical-devices-ivds\" class=\"govuk-link\"\u003eCE marking requirements\u003c/a\u003e have been complied with (or will be complied with prior to the study start).\u003c/p\u003e\n\n\u003ch3 id=\"example-investigational-medical-product-dossiers-impds\"\u003eExample investigational medical product dossiers (IMPDs)\u003c/h3\u003e\n\n\u003cp\u003eIf you are carrying out a trial using modified established medicines, the MHRA has produced some mock examples of completed IMPDs which set out our minimum requirements:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/343466/Over-encapsulation_of_a_tablet.pdf\" class=\"govuk-link\"\u003eOver-encapsulation of a tablet\u003c/a\u003e (PDF, 4.06MB, 5 pages)\u003c/li\u003e\n  \u003cli\u003e\n\u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/343467/Over-encapsulation_of_a_broken_tablet.pdf\" class=\"govuk-link\"\u003eOver-encapsulation of a broken tablet\u003c/a\u003e (PDF, 255KB, 5 pages)\u003c/li\u003e\n  \u003cli\u003e\n\u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/343469/Mock_IMPD_for_PET___non_clinical.pdf\" class=\"govuk-link\"\u003eMock IMPD for PET – non clinical\u003c/a\u003e (PDF, 4.14MB, 7 pages)\u003c/li\u003e\n  \u003cli\u003e\n\u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/343470/Mock_IMPD_for_PET_-_pharmaceutical.pdf\" class=\"govuk-link\"\u003eMock IMPD for PET - pharmaceutical\u003c/a\u003e (PDF, 4.2MB, 14 pages)\u003c/li\u003e\n  \u003cli\u003e\n\u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/317987/Points_to_consider_when_preparing_the_IMP_dossier.pdf\" class=\"govuk-link\"\u003ePoints to consider when preparing the IMP dossier\u003c/a\u003e (PDF, 54.8KB, 3 pages)\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch2 id=\"assessment-of-your-submission\"\u003eAssessment of your submission\u003c/h2\u003e\n\n\u003cp\u003eThe initial combined review assessment will be completed within 30 days of being submitted. Applications for healthy volunteer trials and sponsor-determined phase I trials in non-oncology patients may qualify for a shortened assessment time and MHRA will work with the research ethics committee to endeavour to expedite these applications. You should state on your covering letter if you think your trial is eligible. Note that trial designs that stretch to investigating the benefit of the treatment to participants may not be eligible for the expedited assessment timeframe.\u003c/p\u003e\n\n\u003cp\u003eWe will tell you the outcome of your submission along with the outcome of the research ethics committee review, via the combined review process, which could be:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eacceptance of the request for a clinical trial authorisation\u003c/li\u003e\n  \u003cli\u003eacceptance of the request for a clinical trial authorisation subject to conditions\u003c/li\u003e\n  \u003cli\u003egrounds for non-acceptance of the request for a clinical trial authorisation\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf we raise grounds for non-acceptance you will have the opportunity to respond, usually within 14 days; however this may be extended on request.\u003c/p\u003e\n\n\u003cp\u003eCommunication informing the applicant of the MHRA and ethics committee decision following receipt of the responses will usually be sent within 60 days of us receiving the original valid application. If an extension to the response date has been agreed this will impact the final decision timeline.\u003c/p\u003e\n\n\u003cp\u003eNotification of the decision relating to a gene therapy, somatic cell therapy (including xenogenic cell therapy) product, tissue engineered product, or products containing genetically modified organisms (Regulation 19 of SI1031) will be sent within 90 days of us receiving the original application unless otherwise advised.\u003c/p\u003e\n\n\u003cp\u003eWe have moved from paper to automated electronic communication. To ensure that you receive all our correspondence please ensure that you add \u003ca href=\"mailto:MHRA_CT_Ecomms@mhra.gov.uk\" class=\"govuk-link\"\u003eMHRA_CT_Ecomms@mhra.gov.uk\u003c/a\u003e to your safe sender email list. We will only send official correspondence to the named applicant email address.\u003c/p\u003e\n\n\u003ch2 id=\"common-issues-identified-during-clinical-trial-applications\"\u003eCommon issues identified during clinical trial applications\u003c/h2\u003e\n\n\u003cp\u003eMore than half of all clinical trial authorisation (\u003cabbr title=\"clinical trial authorisation\"\u003eCTA\u003c/abbr\u003e) applications for investigational medicinal products (IMPs) received by the Medicines and Healthcare products Regulatory Agency (MHRA) require additional information to be submitted before they are considered approvable. Many of the issues identified are common and avoidable if available guidance is followed or if a satisfactory justification for not following the applicable guidance is provided in the application.\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003ca href=\"https://www.gov.uk/government/publications/common-issues-identified-during-clinical-trial-applications\" class=\"govuk-link\"\u003eGuidance on the most common issues identified during clinical trial applications and how to avoid them\u003c/a\u003e.\u003c/li\u003e\n  \u003cli\u003eSee our case study: \u003ca href=\"https://www.gov.uk/government/case-studies/early-breast-cancer-patients-benefit-from-a-study-to-potentially-improve-survival-outcomes\" class=\"govuk-link\"\u003eEarly breast cancer patients benefit from a study to potentially improve survival outcomes\u003c/a\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch2 id=\"withdraw-your-request-before-the-final-decision\"\u003eWithdraw your request before the final decision\u003c/h2\u003e\n\n\u003cp\u003eYou may withdraw your request at any point before an assessment decision on your clinical trial authorisation application is reached. It is not possible to withdraw an application once grounds for non-acceptance have been issued.\u003c/p\u003e\n\n\u003cp\u003eTo withdraw an application, please refer to the guidance on the \u003ca rel=\"external\" href=\"https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/clinical-trials-investigational-medicinal-products-ctimps/combined-ways-working-pilot/step-step-guide-using-iras-combined-ways-working-cwow/#withdrawing\" class=\"govuk-link\"\u003eHRA website\u003c/a\u003e.\u003c/p\u003e\n\n\u003ch2 id=\"risk-proportionate-approaches\"\u003eRisk Proportionate Approaches\u003c/h2\u003e\n\n\u003cp\u003eA risk proportionate approach to the initiation, management and monitoring of certain clinical trials is possible. The sponsor should carry out a risk assessment based on the potential risks associated with the IMP. View our guidance on \u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/343677/Risk-adapted_approaches_to_the_management_of_clinical_trials_of_investigational_medicinal_products.pdf\" class=\"govuk-link\"\u003erisk-adapted approaches to the management of clinical trials of investigational medicinal products\u003c/a\u003e.\u003c/p\u003e\n\n\u003cp\u003eWe will perform a risk adapted assessment of certain ‘Type A’ trials in which the risk to the patient from the IMP is considered to be no greater than that of standard medical care. These are trials involving medicinal products licensed in any EU Member State if:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethe trial relates to the licensed range of indications, dosage and form of the product, or;\u003c/li\u003e\n  \u003cli\u003ethe trial involves off-label use (such as in paediatrics and oncology) that is established practice and supported by enough published evidence and/or guidelines.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch2 id=\"new-notification-scheme\"\u003eNew Notification Scheme\u003c/h2\u003e\n\n\u003cp\u003eOur new Notification Scheme enables a more streamlined and risk-proportionate approach to processing clinical trial authorisation (\u003cabbr title=\"clinical trial authorisation\"\u003eCTA\u003c/abbr\u003e) for “initial” applications.\u003c/p\u003e\n\n\u003cp\u003eThe scheme only applies to \u003cabbr title=\"clinical trial authorisation\"\u003eCTA\u003c/abbr\u003e applications for Phase 4 and certain Phase 3 clinical trials deemed to be of lower risk; it does not include \u003cabbr title=\"clinical trial authorisation\"\u003eCTA\u003c/abbr\u003e applications for first in human (FIH), Phase 1 or Phase 2, or amendments at this time.\u003c/p\u003e\n\n\u003cp\u003e\u003cabbr title=\"clinical trial authorisation\"\u003eCTA\u003c/abbr\u003e applications submitted under this scheme will be processed by the MHRA within 14 days, instead of the statutory 30 days, provided the sponsor can demonstrate the trial meets the \u003ca href=\"#new-notification-scheme-criteria\" class=\"govuk-link\"\u003einclusion criteria\u003c/a\u003e. These criteria could change, if the evidence supports the need for this, including the potential to expand the scheme in the future.\u003c/p\u003e\n\n\u003ch3 id=\"register-your-interest-in-our-new-notification-scheme\"\u003eRegister your interest in our new Notification Scheme\u003c/h3\u003e\n\n\u003cdiv class=\"call-to-action\"\u003e\n  \u003cp\u003eApplications under the new Notification Scheme are submitted via the combined review process using the Integrated Research Application System (IRAS); there are no documentation exemptions. You should prepare your complete submission package and submit it in the new part of IRAS as described above.\u003c/p\u003e\n\n  \u003cp\u003eAll applicants (commercials and non-commercials) whose trials meet these criteria should participate in the scheme by registering their interest.\u003c/p\u003e\n\n  \u003cp\u003eComplete \u003ca rel=\"external\" href=\"https://forms.office.com/Pages/ResponsePage.aspx?id=XOon5Vhi0kyif4vSN-xMJsp6Uizarx1OmZz35RhsEuVUMURNSjU4VkQzSExQMFZQUjZSVVdIS0NOMS4u\" class=\"govuk-link\"\u003ethis form\u003c/a\u003e to register your interest.\u003c/p\u003e\n\u003c/div\u003e\n\n\u003cp\u003eMHRA acceptance of an application under the new Notification Scheme will be confirmed within 14 calendar days from the application received effective date and authorisation by the MHRA will be granted unless any criterion is not suitably met . If the MHRA considers the application does not meet the new Notification Scheme criteria, an objection decision will be communicated within 14 calendar days from the application received effective date, and the application will continue under full \u003cabbr title=\"clinical trial authorisation\"\u003eCTA\u003c/abbr\u003e assessment with a decision communicated within the 30-day statutory timeframe.\u003c/p\u003e\n\n\u003cp\u003eApplicants are reminded to ensure \u003ca href=\"https://www.gov.uk/government/publications/common-issues-identified-during-clinical-trial-applications\" class=\"govuk-link\"\u003ecommon issues identified during clinical trial applications\u003c/a\u003e are addressed before submitting their application.\u003c/p\u003e\n\n\u003cp\u003eThe new Notification Scheme is subject to our existing fees. Read \u003ca href=\"#fees\" class=\"govuk-link\"\u003emore information about fees\u003c/a\u003e.\u003c/p\u003e\n\n\u003cp\u003eYou can \u003ca href=\"#contact\" class=\"govuk-link\"\u003econtact us\u003c/a\u003e if you have any questions about the new Notification Scheme.\u003c/p\u003e\n\n\u003ch3 id=\"new-notification-scheme-criteria\"\u003eNew Notification Scheme criteria\u003c/h3\u003e\n\n\u003ch4 id=\"phase-4\"\u003ePhase 4\u003c/h4\u003e\n\n\u003cp\u003ePhase 4 trials are post-marketing or surveillance trials of licensed medicines. They gather information on the drug’s effect across a wider population, side effects associated with long-term use and drug-drug interactions.\u003c/p\u003e\n\n\u003cp\u003ePhase 4 trials must meet both of the following criteria:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eAll investigational medicinal products (IMPs) are licensed and used according to the relevant UK, USA, or EU marketing authorisation (except for placebo)\u003c/li\u003e\n  \u003cli\u003eThere are no ongoing safety concerns with the IMP(s) that the Sponsor is aware of, for example other trials on temporary halt / clinical hold, other trials with unresolved urgent safety measures or post-marketing regulatory restrictions.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch4 id=\"phase-3\"\u003ePhase 3\u003c/h4\u003e\n\n\u003cp\u003eTraditional Phase 3 trials are conducted in more than 300 participants, although there may be exception to this (for example in the cases of rare diseases). They are usually multicentre and include pivotal pre-marketing trials and evaluate the efficacy and safety of the drug, usually with a comparison to placebo or standard of care treatment. They do not include proof of concept, dose-finding, dose-response or proof of efficacy trials, which would usually be labelled Phase 2.\u003c/p\u003e\n\n\u003cp\u003ePhase 3 trials must meet at least one of the following criteria:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe trial is already approved in the USA or EU based on the same protocol and IB versions submitted to MHRA, and for EU approvals, the same version of the IMP dossier.  For trials approved in the USA only, the IMP dossier submitted to the MHRA must document the same IMP manufacturing process.\u003c/li\u003e\n  \u003cli\u003eThe MHRA have approved in the last 2 years a previous phase 3 clinical trial of the IMP(s) at the same dose (or a higher dose), dosing frequency (or a higher frequency), Inclusion of ‘duration (or a longer duration)’ in the criteria for phase 3 trials and route of administration, and for the same indication\u003csup\u003e\u003cstrong\u003e1\u003c/strong\u003e\u003c/sup\u003e (even if the trial was with a different Sponsor) and utilising the same manufacturing process.\u003c/li\u003e\n  \u003cli\u003eIMPs are licensed and used according to the relevant UK, USA, or EU marketing authorisation (except for placebo).\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIn addition, to be eligible for the scheme a Phase 3 trial must \u003cstrong\u003enot\u003c/strong\u003e include any of the following:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eComplex, innovative trial design (e.g. basket, umbrella and platform) that allows for prospective major adaptations such as the addition of indications or IMPs via future amendments\u003csup\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/sup\u003e\n\u003c/li\u003e\n  \u003cli\u003eIncludes paediatric participants\u003csup\u003e\u003cstrong\u003e3\u003c/strong\u003e\u003c/sup\u003e\n\u003c/li\u003e\n  \u003cli\u003eIncludes pregnant or breastfeeding participants\u003c/li\u003e\n  \u003cli\u003eIMP is first in class\u003csup\u003e\u003cstrong\u003e4\u003c/strong\u003e\u003c/sup\u003e\n\u003c/li\u003e\n  \u003cli\u003eIMP is an advanced therapy medicinal product (ATMP)\u003csup\u003e\u003cstrong\u003e5\u003c/strong\u003e\u003c/sup\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u003csup\u003e\u003cstrong\u003e1:\u003c/strong\u003e ‘Same indication’ means the same target disease*, of the same severity, in the same age group and (if relevant) in the same drug combination or line of treatment. This should be as per the stated eligibility criteria.  *A subset/subtype of the target disease is not considered to be the same.\u003c/sup\u003e\n\u003cbr\u003e\n\u003csup\u003e\u003cstrong\u003e2:\u003c/strong\u003e Trials with complex innovative designs: \u003ca rel=\"external\" href=\"https://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2019_02_CTFG_Recommendation_paper_on_Complex_Clinical_Trials.pdf\" class=\"govuk-link\"\u003e\u003cabbr title=\"Clinical Trials Facilitation Group\"\u003eCTFG\u003c/abbr\u003e Recommendation paper on complex clinical trials (12 February 2019)\u003c/a\u003e. \n\u003cbr\u003e\nBlagden, S.P., Billingham, L., Brown, L.C. et al. \u003ca rel=\"external\" href=\"https://www.nature.com/articles/s41416-019-0653-9\" class=\"govuk-link\"\u003eEffective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement. Br J Cancer 122, 473–482 (2020)\u003c/a\u003e.\u003c/sup\u003e\n\u003cbr\u003e\n\u003csup\u003e\u003cstrong\u003e3:\u003c/strong\u003e Under 18 years of age\u003c/sup\u003e\n\u003cbr\u003e\n\u003csup\u003e\u003cstrong\u003e4:\u003c/strong\u003e A first-in-class IMP uses a new and unique mechanism of action to treat a medical condition or disease.\u003c/sup\u003e\n\u003cbr\u003e\n\u003csup\u003e\u003cstrong\u003e5:\u003c/strong\u003e An ATMP is a medicinal product which is either: a gene therapy medicinal product, a somatic cell therapy medicinal product, or a tissue engineered product.  A definition of ATMPs is found in Directive 2001/83/EC as amended by the ATMP Regulation 1394/2007 and includes combination ATMPs.\u003c/sup\u003e\u003c/p\u003e\n\n\u003ch2 id=\"requesting-approval-of-trials-with-complex-innovative-designs\"\u003eRequesting approval of trials with complex innovative designs\u003c/h2\u003e\n\n\u003cp\u003eThe MHRA supports the conduct of trials with complex innovative designs such as umbrella, basket, platform and master protocol plus submodules.\u003c/p\u003e\n\n\u003cp\u003eThese trial designs are characterised by the presence of prospective major adaptations.\u003c/p\u003e\n\n\u003cp\u003eExamples of major adaptations are addition of new investigational medicinal products or introducing new trial populations.\u003c/p\u003e\n\n\u003cp\u003eThe Sponsor should choose the best design to address the trial objectives, to ensure that the benefit-risk balance of the trial is positive and to ensure the reliability of results.\u003c/p\u003e\n\n\u003cp\u003eWhen submitting a Clinical Trial Authorisation application for a trial with prospective major adaptations the trial Sponsor needs to justify the choice of a complex trial design, ensure that each adaptation as well as the entire trial are safe and scientifically sound and describe how the integrity of trial results will be maintained throughout the conduct of the trial.\u003c/p\u003e\n\n\u003cp\u003eSome points to consider when planning a complex innovative design trial can be found in the article \u003ca rel=\"external\" href=\"https://www.nature.com/articles/s41416-019-0653-9\" class=\"govuk-link\"\u003eBlagden, S.P., Billingham, L., Brown, L.C. et al. Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement. Br J Cancer 122, 473–482 (2020)\u003c/a\u003e.\u003c/p\u003e\n\n\u003cp\u003eAlthough the paper is written for cancer trials the recommendations can apply to trials in other indications.\u003c/p\u003e\n\n\u003ch3 id=\"major-adaptations-introduced-via-substantial-amendments\"\u003eMajor adaptations introduced via substantial amendments\u003c/h3\u003e\n\n\u003cp\u003eIt may be appropriate to propose major adaptations via submission of a substantial amendment request.\u003c/p\u003e\n\n\u003cp\u003eTwo scenarios can occur.\u003c/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eIf a trial was approved as a trial with complex innovative design introduction of future major adaptations will be consistent with the original trial objectives. Sponsors need to seek approval from the MHRA before implementing major adaptations if they were not fully described in the protocol approved at the time of the initial application. If the proposed changes are safe and scientifically sound they will be deemed approvable by the MHRA when reviewing the substantial amendment application.\u003c/li\u003e\n  \u003cli\u003eIt is understood that in some cases major adaptations may be necessary for trials with a design that did not envisage future significant adaptations (i.e. not complex innovative designs such as umbrella, basket and platform). In this case when submitting the substantial amendment request the trial Sponsor needs to address in writing the following points:\u003c/li\u003e\n\u003c/ol\u003e\n\n\u003cul\u003e\n  \u003cli\u003ea strong rationale must be provided why the major adaptations should be implemented in the current trial and why they do not constitute a new trial;\u003c/li\u003e\n  \u003cli\u003ean explanation why the adaptations are safe and scientifically sound\u003c/li\u003e\n  \u003cli\u003edeclaration that the introduction of the proposed changes does not jeopardise trial integrity, i.e. the use and analysis of the data generated by the trial up to the time of the proposed adaptations.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf a robust rationale is not provided at the time of submission of a substantial amendment, the request may be refused. Indeed also, if the rationale is not deemed acceptable by the regulator or any of the points above have not been adequately addressed the request may be refused.\u003c/p\u003e\n\n\u003cp\u003eBefore submitting an application for authorisation of a trial with complex innovative design and/or an amendment requesting approval of major adaptations Sponsors are recommended to establish a dialogue with the MHRA and seek advice.\u003c/p\u003e\n\n\u003cp\u003eSponsors should consult our guidance on \u003ca href=\"https://www.gov.uk/guidance/medicines-get-scientific-advice-from-mhra\" class=\"govuk-link\"\u003eHow to seek advice from the MHRA\u003c/a\u003e.\u003c/p\u003e\n\n\u003ch2 id=\"applications-that-need-expert-advice\"\u003eApplications that need expert advice\u003c/h2\u003e\n\n\u003cp\u003eFor certain trials, we will seek advice from the Clinical Trials, Biologicals and Vaccines Expert Advisory Group (CTBVEAG) of the Commission on Human Medicines (CHM). The CHM will then discuss the trial at their meeting, which will take place later in the same week as the CTBVEAG meeting. We will make the decision to refer applications for expert advice based on an assessment of the risks and how the sponsor plans to mitigate them. Areas we look at when considering risk factors include:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003emode of action\u003c/li\u003e\n  \u003cli\u003enature of the target\u003c/li\u003e\n  \u003cli\u003erelevance of animal species and models\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eWe may refer other applications for expert advice if we identify issues during the assessment process.\nExamples of trials where expert advice may be needed include first-in-human (FIH) trials with novel compounds where the:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003emode of action involves a target that is connected to multiple signalling pathways (target with pleiotropic effects), e.g. leading to various physiological effects or targets that are ubiquitously expressed\u003c/li\u003e\n  \u003cli\u003ecompound acts (directly or indirectly) via a cascade system where there may be an amplification effect which might not be sufficiently controlled by a physiological feedback mechanism\u003c/li\u003e\n  \u003cli\u003ecompound acts (directly or indirectly) via the immune system with a target or mechanism of action which is novel or currently not well characterised\u003c/li\u003e\n  \u003cli\u003eis novelty in the structure of the active substance e.g. a new type of engineered structural format such as those with enhanced receptor interaction as compared with the parent compound\u003c/li\u003e\n  \u003cli\u003elevel of expression and biological function of the target receptor may differ between healthy individuals and patients with the relevant disease\u003c/li\u003e\n  \u003cli\u003eis insufficient available knowledge of the structure, tissue distribution, cell specificity, disease specificity, regulation, level of expression and biological function of the human target, including down-stream effects\u003c/li\u003e\n  \u003cli\u003ecompound acts via a possible or likely species specific mechanism or where animal data are unlikely to be predictive of activity in humans\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf you are a sponsor of a FIH or early stage clinical trial you should read the \u003ca rel=\"external\" href=\"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational_en.pdf\" class=\"govuk-link\"\u003eGuideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products\u003c/a\u003e. You should use the document to help you identify risk factors and create mitigation strategies.\u003c/p\u003e\n\n\u003cp\u003eSponsors should use the criteria above to decide if their trial needs expert advice. You can get pre-submission advice from us if you are unsure if your compound falls into the ‘higher-risk’ category.\u003c/p\u003e\n\n\u003cp\u003eTo get advice you should send an email with ‘URGENT – EAG/CHM QUERY’ as the title to \u003ca href=\"mailto:clintrialhelpline@mhra.gov.uk\" class=\"govuk-link\"\u003eclintrialhelpline@mhra.gov.uk\u003c/a\u003e including:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ea summary of the nature of the compound\u003c/li\u003e\n  \u003cli\u003eits target/mechanism of action\u003c/li\u003e\n  \u003cli\u003ethe relevance of the animal model(s)\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eWe will send a response to this email within 14 days.\u003c/p\u003e\n\n\u003cp\u003eIf we confirm that the application comes within the category of ‘higher risk’, or you have determined this yourself, you should \u003ca href=\"https://www.gov.uk/government/organisations/commission-on-human-medicines/about/membership#clinical-trials-biologicals-and-vaccines-eag\" class=\"govuk-link\"\u003eselect the date of the CTBVEAG meeting\u003c/a\u003e where you want your trial discussed.\u003c/p\u003e\n\n\u003cp\u003eYou should prepare your complete submission package and submit it in the new part of IRAS as described above.\u003c/p\u003e\n\n\u003cp\u003eAt least 14 days prior to submission you should alert MHRA and HRA (\u003ca href=\"mailto:clintrialhelpline@mhra.gov.uk\" class=\"govuk-link\"\u003eclintrialhelpline@mhra.gov.uk\u003c/a\u003e); \u003ca href=\"mailto:approvals@hra.nhs.uk\" class=\"govuk-link\"\u003eapprovals@hra.nhs.uk\u003c/a\u003e) that the application is planned and it requires EAG/CHM review. To ensure an appropriate \u003cabbr title=\"Research Ethics Committee\"\u003eREC\u003c/abbr\u003e meeting is scheduled, relevant study information such as the IRAS ID (if available) and whether your study involves the use of an Advanced Therapy Medicinal Product (ATMP) is required. It is recommended that an IRAS ID is obtained prior to alerting the MHRA and HRA of this planned submission and included in the email notification.\nThe rest of the application process is as described above for all applications. The combined response letter will be sent to the sponsor as soon as possible after the \u003cabbr title=\"Research Ethics Committee\"\u003eREC\u003c/abbr\u003e meeting. Please refer to HRA website for further information regarding scheduling of the \u003cabbr title=\"Research Ethics Committee\"\u003eREC\u003c/abbr\u003e meeting.\u003c/p\u003e\n\n\u003ch3 id=\"chm-areas-for-discussion\"\u003eCHM areas for discussion\u003c/h3\u003e\n\n\u003cp\u003eAt the CHM meeting the experts will discuss your application, including the responses you provide to the CHM areas for discussion. These are:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethe function of the target in man\u003c/li\u003e\n  \u003cli\u003ethe ability of the subject to maintain a normal physiological response to challenge in the presence of the investigational product\u003c/li\u003e\n  \u003cli\u003ethe transition from preclinical to human testing, particularly with regard to highly species-specific molecules\u003c/li\u003e\n  \u003cli\u003ethe potential for on-target and off-target effects and how this will be handled in the clinic\u003c/li\u003e\n  \u003cli\u003ethe doses used in the relevant animal species (particularly with regard to the use in the animal model of the starting dose to be administered to man)\u003c/li\u003e\n  \u003cli\u003ea rationale for the starting dose in man (including, for example receptor occupancy)\u003c/li\u003e\n  \u003cli\u003ea rationale for the study population (particularly for the use of healthy volunteers)\u003c/li\u003e\n  \u003cli\u003ea rationale for the administration schedule for the initial and subsequent cohorts - this should include the time interval between doses administered to individual subjects\u003c/li\u003e\n  \u003cli\u003ea rationale for the dose escalation particularly with regard to potential adverse effect\u003c/li\u003e\n  \u003cli\u003ea rationale for the proposed trial site, including the facilities available\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch3 id=\"trials-in-patients-previously-treated-with-an-advanced-therapy-medicinal-product\"\u003eTrials in patients previously treated with an Advanced Therapy Medicinal Product\u003c/h3\u003e\n\n\u003cp\u003ePrevious use of an Advanced Therapy Medicinal Product (ATMP) was a standard exclusion criterion for participation in a clinical trial. Recent data show that despite previous ATMP administration some patients present with disease progression or relapse. Administration of a new Investigational Medicinal Product (IMP) could therefore be justifiable.\u003c/p\u003e\n\n\u003cp\u003e\u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/735741/Points_to_consider_for_trials_allowing_inclusion_of_patients_previously_treated_with_an_Advanced_Therapy_Medicinal_Product_Web.pdf\" class=\"govuk-link\"\u003ePoints to consider for trials allowing inclusion of patients previously treated with an Advanced Therapy Medicinal Product\u003c/a\u003e identifies the main points to consider when proposing trials of an IMP administered after previous ATMP use.\u003c/p\u003e\n\n\u003ch2 id=\"fees\"\u003eFees\u003c/h2\u003e\n\n\u003cp\u003eThere are different fees based on your \u003ca href=\"https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees#clinical-trials-application-fees\" class=\"govuk-link\"\u003etype of clinical trial application\u003c/a\u003e. The fees applied to the New Notification Scheme are listed under \u003ca href=\"https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees#clinical-trials-application-fees\" class=\"govuk-link\"\u003eClinical trials: applications fees\u003c/a\u003e.\u003c/p\u003e\n\n\u003cp\u003eFor the purposes of fee determination, an application supported by quality data for blinding purposes (for example, placebo comparator or over-encapsulation) remains within the category of applications without an IMPD.\u003c/p\u003e\n\n\u003cp\u003eInvoices for Clinical Trial Authorisation applications, Substantial Amendment applications, and Annual Safety Reports are sent directly to the applicant shortly after a valid submission has been established. The covering letter for the application should clearly highlight your Purchase Order (PO) number where available. The applicant is the person listed in section C1 of the Application form, or section D1 of the Amendment form. We are unable to address the invoice to someone other than those listed in the sections above.\u003c/p\u003e\n\n\u003cp\u003eIt is the responsibility of the applicant to ensure timely payment of invoices for their submissions. Invoices must be settled on receipt of invoice. Penalty fees may be incurred for non-payment, details of the penalties are set out in the \u003ca rel=\"external\" href=\"https://www.legislation.gov.uk/uksi/2016/190/contents\" class=\"govuk-link\"\u003eFees Regulations\u003c/a\u003e. Non-payment may also result in suspension of any licence or authorisation, followed by legal proceedings for unpaid amounts, as a debt due to the Crown.\u003c/p\u003e\n\n\u003cp\u003eYou can contact MHRA Finance Department on 020 3080 6533 or email \u003ca href=\"mailto:sales.invoices@mhra.gov.uk\" class=\"govuk-link\"\u003esales.invoices@mhra.gov.uk\u003c/a\u003e for more information on how to pay fees.\u003c/p\u003e\n\n\u003ch2 id=\"contact\"\u003eContact\u003c/h2\u003e\n\n\u003cp\u003eFor information about your submission, including status and tracking enquiries, contact the clinical trials helpline on 020 3080 6456 (Monday to Friday 8:30am to 4.30pm) or email \u003ca href=\"mailto:clintrialhelpline@mhra.gov.uk\" class=\"govuk-link\"\u003eclintrialhelpline@mhra.gov.uk\u003c/a\u003e. See \u003ca href=\"https://www.gov.uk/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues#clinical-trials-named-contact\" class=\"govuk-link\"\u003eClinical trials named contact\u003c/a\u003e for further information.\u003c/p\u003e\n\n\u003c/div\u003e",
                    "change_history":  [
                                           {
                                               "note":  "Amendment made to IVDs text on clinical trial/investigation webpages",
                                               "public_timestamp":  "2024-08-27T11:43:37.000+01:00"
                                           },
                                           {
                                               "note":  "Updated the Combined IMP Device guidance attachment.",
                                               "public_timestamp":  "2024-04-10T12:57:00.000+01:00"
                                           },
                                           {
                                               "note":  "Added Combined IMP device guidance section and attachment. ",
                                               "public_timestamp":  "2024-04-10T10:48:23.000+01:00"
                                           },
                                           {
                                               "note":  "Added link to case study: \u0027Agile, responsive regulation helps early breast cancer patients to benefit from a study to potentially improve survival outcomes\u0027 to section \u0027Common issues identified during clinical trial applications\u0027.",
                                               "public_timestamp":  "2024-03-28T10:00:00.000+00:00"
                                           },
                                           {
                                               "note":  "Added document \u0027Tabular Summary input (template) for non marked IVD devices\u0027.",
                                               "public_timestamp":  "2023-12-14T13:50:37.000+00:00"
                                           },
                                           {
                                               "note":  "Added information about the New Notification Scheme.",
                                               "public_timestamp":  "2023-10-12T09:00:04.000+01:00"
                                           },
                                           {
                                               "note":  "New section about In Vitro Diagnostic Medical Devices (IVDs) has been included.",
                                               "public_timestamp":  "2023-06-26T12:45:35.000+01:00"
                                           },
                                           {
                                               "note":  "Added information on \u0027Requesting approval of trials with complex innovative designs\u0027.",
                                               "public_timestamp":  "2022-07-18T15:53:53.000+01:00"
                                           },
                                           {
                                               "note":  "Included information about the new combined review service.",
                                               "public_timestamp":  "2022-01-07T12:00:34.000+00:00"
                                           },
                                           {
                                               "note":  "Updated the note regarding CTIMP applications",
                                               "public_timestamp":  "2021-10-26T12:07:57.000+01:00"
                                           },
                                           {
                                               "note":  "Updated the information regarding the combined review service.",
                                               "public_timestamp":  "2021-10-21T14:45:42.000+01:00"
                                           },
                                           {
                                               "note":  "Updated details on \u0027When a clinical trial authorisation (CTA) is needed\u0027",
                                               "public_timestamp":  "2021-09-30T12:51:51.000+01:00"
                                           },
                                           {
                                               "note":  "Update about the \u0027SCOPE\u0027 advice service. From October 2021 the ‘SCOPE’ advice service will only be available via self-service using the guidance on this webpage. ",
                                               "public_timestamp":  "2021-06-24T09:48:25.000+01:00"
                                           },
                                           {
                                               "note":  "Updated guidance for the registration of clinical trials. ",
                                               "public_timestamp":  "2021-03-18T15:15:21.000+00:00"
                                           },
                                           {
                                               "note":  "Following the end of the transition period, removed information about using EC systems like CESP, published new information about the notification scheme and submitting a clinical trial authorisation application form.",
                                               "public_timestamp":  "2021-01-01T12:13:16.000+00:00"
                                           },
                                           {
                                               "note":  "Change to covering letter requirements and fees section",
                                               "public_timestamp":  "2020-10-16T12:54:07.000+01:00"
                                           },
                                           {
                                               "note":  "Added contact information on Clinical Trial Application form section.",
                                               "public_timestamp":  "2019-10-25T09:18:16.000+01:00"
                                           },
                                           {
                                               "note":  "New information and \u0027request form\u0027 added to the section \u0027when a clinical trial authorisation is needed\u0027.",
                                               "public_timestamp":  "2019-06-25T12:04:16.000+01:00"
                                           },
                                           {
                                               "note":  "Addition of document covering Points to consider for trials allowing inclusion of patients previously treated with an Advanced Therapy Medicinal Product",
                                               "public_timestamp":  "2018-08-23T12:24:05.000+01:00"
                                           },
                                           {
                                               "note":  "Updated common errors PDF.",
                                               "public_timestamp":  "2018-03-12T15:25:35.000+00:00"
                                           },
                                           {
                                               "note":  "Additional information added to the section: Documents to send with your application.",
                                               "public_timestamp":  "2017-08-04T10:42:06.000+01:00"
                                           },
                                           {
                                               "note":  "Updated clinical trial mock examples.",
                                               "public_timestamp":  "2017-05-18T13:25:38.000+01:00"
                                           },
                                           {
                                               "note":  "Information about proof of payment requirements updated.",
                                               "public_timestamp":  "2017-03-31T12:03:48.000+01:00"
                                           },
                                           {
                                               "note":  "Updated to include a link to guidance on common issues identified during clinical trial applications and how to avoid them.",
                                               "public_timestamp":  "2017-03-27T15:19:08.000+01:00"
                                           },
                                           {
                                               "note":  "Updated contact information for fee section.",
                                               "public_timestamp":  "2017-01-24T09:38:52.000+00:00"
                                           },
                                           {
                                               "note":  "Additional information about applications for trials involving CAR-T cell medical products added to the page.",
                                               "public_timestamp":  "2017-01-12T13:22:46.000+00:00"
                                           },
                                           {
                                               "note":  "Updated contact information.",
                                               "public_timestamp":  "2017-01-03T11:17:01.000+00:00"
                                           },
                                           {
                                               "note":  "Contact information updated.",
                                               "public_timestamp":  "2016-12-20T11:38:24.000+00:00"
                                           },
                                           {
                                               "note":  "Updated information under \u0027Assessment of your submission’.",
                                               "public_timestamp":  "2016-11-28T13:42:30.000+00:00"
                                           },
                                           {
                                               "note":  "Physical media submissions (CD/DVD) for medicines licences and clinical trial applications will not be accepted from 1 February 2016.",
                                               "public_timestamp":  "2016-02-01T14:16:51.000+00:00"
                                           },
                                           {
                                               "note":  "First published.",
                                               "public_timestamp":  "2014-12-18T00:00:00.000+00:00"
                                           }
                                       ],
                    "emphasised_organisations":  [
                                                     "240f72bd-9a4d-4f39-94d9-77235cadde8e"
                                                 ],
                    "first_public_at":  "2014-12-18T00:00:00.000+00:00",
                    "political":  false,
                    "related_mainstream_content":  [

                                                   ],
                    "tags":  {
                                 "browse_pages":  [

                                                  ]
                             }
                },
    "document_type":  "detailed_guide",
    "first_published_at":  "2014-12-18T00:00:00+00:00",
    "links":  {
                  "available_translations":  [
                                                 {
                                                     "api_path":  "/api/content/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                     "api_url":  "https://www.gov.uk/api/content/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                     "base_path":  "/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                     "content_id":  "5f5ea58c-7631-11e4-a3cb-005056011aef",
                                                     "document_type":  "detailed_guide",
                                                     "links":  {

                                                               },
                                                     "locale":  "en",
                                                     "public_updated_at":  "2024-08-27T10:43:37Z",
                                                     "schema_name":  "detailed_guide",
                                                     "title":  "Clinical trials for medicines: apply for authorisation in the UK",
                                                     "web_url":  "https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                     "withdrawn":  false
                                                 }
                                             ],
                  "document_collections":  [
                                               {
                                                   "api_path":  "/api/content/government/collections/clinical-trials-for-medicines",
                                                   "api_url":  "https://www.gov.uk/api/content/government/collections/clinical-trials-for-medicines",
                                                   "base_path":  "/government/collections/clinical-trials-for-medicines",
                                                   "content_id":  "4dfda159-a98b-4fe9-94cc-964cf3bd65a0",
                                                   "document_type":  "document_collection",
                                                   "links":  {
                                                                 "documents":  [
                                                                                   {
                                                                                       "api_path":  "/api/content/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "api_url":  "https://www.gov.uk/api/content/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "base_path":  "/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "content_id":  "5f5ea58c-7631-11e4-a3cb-005056011aef",
                                                                                       "document_type":  "detailed_guide",
                                                                                       "links":  {

                                                                                                 },
                                                                                       "locale":  "en",
                                                                                       "public_updated_at":  "2024-08-27T10:43:37Z",
                                                                                       "schema_name":  "detailed_guide",
                                                                                       "title":  "Clinical trials for medicines: apply for authorisation in the UK",
                                                                                       "web_url":  "https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "withdrawn":  false
                                                                                   }
                                                                               ]
                                                             },
                                                   "locale":  "en",
                                                   "public_updated_at":  "2014-12-18T18:17:00Z",
                                                   "schema_name":  "document_collection",
                                                   "title":  "Clinical trials for medicines",
                                                   "web_url":  "https://www.gov.uk/government/collections/clinical-trials-for-medicines",
                                                   "withdrawn":  false
                                               },
                                               {
                                                   "api_path":  "/api/content/government/collections/medicines-clinical-trials",
                                                   "api_url":  "https://www.gov.uk/api/content/government/collections/medicines-clinical-trials",
                                                   "base_path":  "/government/collections/medicines-clinical-trials",
                                                   "content_id":  "86443e27-1b35-4658-b6ea-cd609269d626",
                                                   "document_type":  "document_collection",
                                                   "links":  {
                                                                 "documents":  [
                                                                                   {
                                                                                       "api_path":  "/api/content/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "api_url":  "https://www.gov.uk/api/content/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "base_path":  "/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "content_id":  "5f5ea58c-7631-11e4-a3cb-005056011aef",
                                                                                       "document_type":  "detailed_guide",
                                                                                       "links":  {

                                                                                                 },
                                                                                       "locale":  "en",
                                                                                       "public_updated_at":  "2024-08-27T10:43:37Z",
                                                                                       "schema_name":  "detailed_guide",
                                                                                       "title":  "Clinical trials for medicines: apply for authorisation in the UK",
                                                                                       "web_url":  "https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "withdrawn":  false
                                                                                   }
                                                                               ]
                                                             },
                                                   "locale":  "en",
                                                   "public_updated_at":  "2023-09-21T13:10:00Z",
                                                   "schema_name":  "document_collection",
                                                   "title":  "Medicines: clinical trials",
                                                   "web_url":  "https://www.gov.uk/government/collections/medicines-clinical-trials",
                                                   "withdrawn":  false
                                               },
                                               {
                                                   "api_path":  "/api/content/government/collections/services-and-information",
                                                   "api_url":  "https://www.gov.uk/api/content/government/collections/services-and-information",
                                                   "base_path":  "/government/collections/services-and-information",
                                                   "content_id":  "9d1aca0a-6c2c-4314-8196-811649a88e10",
                                                   "document_type":  "document_collection",
                                                   "links":  {
                                                                 "documents":  [
                                                                                   {
                                                                                       "api_path":  "/api/content/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "api_url":  "https://www.gov.uk/api/content/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "base_path":  "/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "content_id":  "5f5ea58c-7631-11e4-a3cb-005056011aef",
                                                                                       "document_type":  "detailed_guide",
                                                                                       "links":  {

                                                                                                 },
                                                                                       "locale":  "en",
                                                                                       "public_updated_at":  "2024-08-27T10:43:37Z",
                                                                                       "schema_name":  "detailed_guide",
                                                                                       "title":  "Clinical trials for medicines: apply for authorisation in the UK",
                                                                                       "web_url":  "https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk",
                                                                                       "withdrawn":  false
                                                                                   }
                                                                               ]
                                                             },
                                                   "locale":  "en",
                                                   "public_updated_at":  "2023-03-29T16:28:44Z",
                                                   "schema_name":  "document_collection",
                                                   "title":  "Services and information",
                                                   "web_url":  "https://www.gov.uk/government/collections/services-and-information",
                                                   "withdrawn":  false
                                               }
                                           ],
                  "government":  [
                                     {
                                         "api_path":  "/api/content/government/2010-to-2015-conservative-and-liberal-democrat-coalition-government",
                                         "api_url":  "https://www.gov.uk/api/content/government/2010-to-2015-conservative-and-liberal-democrat-coalition-government",
                                         "base_path":  "/government/2010-to-2015-conservative-and-liberal-democrat-coalition-government",
                                         "content_id":  "591c83aa-3b74-437d-a342-612bddd97572",
                                         "details":  {
                                                         "current":  false,
                                                         "ended_on":  "2015-05-08T00:00:00+00:00",
                                                         "started_on":  "2010-05-12T00:00:00+00:00"
                                                     },
                                         "document_type":  "government",
                                         "links":  {

                                                   },
                                         "locale":  "en",
                                         "title":  "2010 to 2015 Conservative and Liberal Democrat coalition government",
                                         "web_url":  "https://www.gov.uk/government/2010-to-2015-conservative-and-liberal-democrat-coalition-government"
                                     }
                                 ],
                  "lead_organisations":  [
                                             {
                                                 "analytics_identifier":  "EA63",
                                                 "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                 "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                 "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                 "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                                 "details":  {
                                                                 "acronym":  "MHRA",
                                                                 "brand":  "department-of-health",
                                                                 "default_news_image":  null,
                                                                 "logo":  {
                                                                              "crest":  "single-identity",
                                                                              "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                          },
                                                                 "organisation_govuk_status":  {
                                                                                                   "status":  "live",
                                                                                                   "updated_at":  null,
                                                                                                   "url":  null
                                                                                               }
                                                             },
                                                 "document_type":  "organisation",
                                                 "links":  {

                                                           },
                                                 "locale":  "en",
                                                 "schema_name":  "organisation",
                                                 "title":  "Medicines and Healthcare products Regulatory Agency",
                                                 "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                 "withdrawn":  false
                                             }
                                         ],
                  "organisations":  [
                                        {
                                            "analytics_identifier":  "EA63",
                                            "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                            "details":  {
                                                            "acronym":  "MHRA",
                                                            "brand":  "department-of-health",
                                                            "default_news_image":  null,
                                                            "logo":  {
                                                                         "crest":  "single-identity",
                                                                         "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                     },
                                                            "organisation_govuk_status":  {
                                                                                              "status":  "live",
                                                                                              "updated_at":  null,
                                                                                              "url":  null
                                                                                          }
                                                        },
                                            "document_type":  "organisation",
                                            "links":  {

                                                      },
                                            "locale":  "en",
                                            "schema_name":  "organisation",
                                            "title":  "Medicines and Healthcare products Regulatory Agency",
                                            "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "withdrawn":  false
                                        }
                                    ],
                  "original_primary_publishing_organisation":  [
                                                                   {
                                                                       "analytics_identifier":  "EA63",
                                                                       "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                                                       "details":  {
                                                                                       "acronym":  "MHRA",
                                                                                       "brand":  "department-of-health",
                                                                                       "default_news_image":  null,
                                                                                       "logo":  {
                                                                                                    "crest":  "single-identity",
                                                                                                    "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                                                },
                                                                                       "organisation_govuk_status":  {
                                                                                                                         "status":  "live",
                                                                                                                         "updated_at":  null,
                                                                                                                         "url":  null
                                                                                                                     }
                                                                                   },
                                                                       "document_type":  "organisation",
                                                                       "links":  {

                                                                                 },
                                                                       "locale":  "en",
                                                                       "schema_name":  "organisation",
                                                                       "title":  "Medicines and Healthcare products Regulatory Agency",
                                                                       "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "withdrawn":  false
                                                                   }
                                                               ],
                  "primary_publishing_organisation":  [
                                                          {
                                                              "analytics_identifier":  "EA63",
                                                              "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                                              "details":  {
                                                                              "acronym":  "MHRA",
                                                                              "brand":  "department-of-health",
                                                                              "default_news_image":  null,
                                                                              "logo":  {
                                                                                           "crest":  "single-identity",
                                                                                           "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                                       },
                                                                              "organisation_govuk_status":  {
                                                                                                                "status":  "live",
                                                                                                                "updated_at":  null,
                                                                                                                "url":  null
                                                                                                            }
                                                                          },
                                                              "document_type":  "organisation",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "schema_name":  "organisation",
                                                              "title":  "Medicines and Healthcare products Regulatory Agency",
                                                              "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "withdrawn":  false
                                                          }
                                                      ],
                  "related_guides":  [
                                         {
                                             "api_path":  "/api/content/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues",
                                             "api_url":  "https://www.gov.uk/api/content/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues",
                                             "base_path":  "/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues",
                                             "content_id":  "5f5ea66c-7631-11e4-a3cb-005056011aef",
                                             "document_type":  "detailed_guide",
                                             "links":  {

                                                       },
                                             "locale":  "en",
                                             "public_updated_at":  "2024-03-26T15:21:11Z",
                                             "schema_name":  "detailed_guide",
                                             "title":  "Clinical trials for medicines: manage your authorisation, report safety issues",
                                             "web_url":  "https://www.gov.uk/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues",
                                             "withdrawn":  false
                                         }
                                     ],
                  "suggested_ordered_related_items":  [
                                                          {
                                                              "api_path":  "/api/content/government/publications/common-issues-identified-during-clinical-trial-applications",
                                                              "api_url":  "https://www.gov.uk/api/content/government/publications/common-issues-identified-during-clinical-trial-applications",
                                                              "base_path":  "/government/publications/common-issues-identified-during-clinical-trial-applications",
                                                              "content_id":  "d1f6ff7b-24b0-4bb8-8332-b3d1e2ae378e",
                                                              "document_type":  "guidance",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2023-11-06T15:14:10Z",
                                                              "schema_name":  "publication",
                                                              "title":  "Common issues identified during clinical trial applications",
                                                              "web_url":  "https://www.gov.uk/government/publications/common-issues-identified-during-clinical-trial-applications",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/guidance-on-substantial-amendments-to-a-clinical-trial",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/guidance-on-substantial-amendments-to-a-clinical-trial",
                                                              "base_path":  "/guidance/guidance-on-substantial-amendments-to-a-clinical-trial",
                                                              "content_id":  "0a68f0be-ef32-406d-a7c6-d892bfa6e5c6",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2020-12-31T23:01:00Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Guidance on substantial amendments to a clinical trial",
                                                              "web_url":  "https://www.gov.uk/guidance/guidance-on-substantial-amendments-to-a-clinical-trial",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/government/collections/clinical-trials-for-medicines",
                                                              "api_url":  "https://www.gov.uk/api/content/government/collections/clinical-trials-for-medicines",
                                                              "base_path":  "/government/collections/clinical-trials-for-medicines",
                                                              "content_id":  "4dfda159-a98b-4fe9-94cc-964cf3bd65a0",
                                                              "document_type":  "document_collection",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2014-12-18T18:17:00Z",
                                                              "schema_name":  "document_collection",
                                                              "title":  "Clinical trials for medicines",
                                                              "web_url":  "https://www.gov.uk/government/collections/clinical-trials-for-medicines",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/medicines-get-scientific-advice-from-mhra",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/medicines-get-scientific-advice-from-mhra",
                                                              "base_path":  "/guidance/medicines-get-scientific-advice-from-mhra",
                                                              "content_id":  "2e97f03d-e0e5-4757-923d-15d8f854d55e",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2022-03-25T14:04:18Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Medicines: get scientific advice from MHRA",
                                                              "web_url":  "https://www.gov.uk/guidance/medicines-get-scientific-advice-from-mhra",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues",
                                                              "base_path":  "/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues",
                                                              "content_id":  "5f5ea66c-7631-11e4-a3cb-005056011aef",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2024-03-26T15:21:11Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Clinical trials for medicines: manage your authorisation, report safety issues",
                                                              "web_url":  "https://www.gov.uk/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues",
                                                              "withdrawn":  false
                                                          }
                                                      ],
                  "taxons":  [
                                 {
                                     "api_path":  "/api/content/health-and-social-care/medicines-medical-devices-blood-clinical-trials-investigations",
                                     "api_url":  "https://www.gov.uk/api/content/health-and-social-care/medicines-medical-devices-blood-clinical-trials-investigations",
                                     "base_path":  "/health-and-social-care/medicines-medical-devices-blood-clinical-trials-investigations",
                                     "content_id":  "6949bbe9-60c0-4782-9cdf-873db42514d3",
                                     "details":  {
                                                     "internal_name":  "Clinical trials and investigations [T]",
                                                     "notes_for_editors":  "",
                                                     "visible_to_departmental_editors":  false
                                                 },
                                     "document_type":  "taxon",
                                     "links":  {
                                                   "parent_taxons":  [
                                                                         {
                                                                             "api_path":  "/api/content/health-and-social-care/medicines-medical-devices-blood",
                                                                             "api_url":  "https://www.gov.uk/api/content/health-and-social-care/medicines-medical-devices-blood",
                                                                             "base_path":  "/health-and-social-care/medicines-medical-devices-blood",
                                                                             "content_id":  "cebc01ee-f70a-4397-a552-622e10b62508",
                                                                             "description":  "",
                                                                             "details":  {
                                                                                             "internal_name":  "Medicines and medical devices [T] (level 2, health theme)",
                                                                                             "notes_for_editors":  "",
                                                                                             "visible_to_departmental_editors":  false
                                                                                         },
                                                                             "document_type":  "taxon",
                                                                             "links":  {
                                                                                           "parent_taxons":  [
                                                                                                                 {
                                                                                                                     "api_path":  "/api/content/health-and-social-care",
                                                                                                                     "api_url":  "https://www.gov.uk/api/content/health-and-social-care",
                                                                                                                     "base_path":  "/health-and-social-care",
                                                                                                                     "content_id":  "8124ead8-8ebc-4faf-88ad-dd5cbcc92ba8",
                                                                                                                     "description":  "",
                                                                                                                     "details":  {
                                                                                                                                     "internal_name":  "Health and social care",
                                                                                                                                     "notes_for_editors":  "",
                                                                                                                                     "visible_to_departmental_editors":  true
                                                                                                                                 },
                                                                                                                     "document_type":  "taxon",
                                                                                                                     "links":  {
                                                                                                                                   "root_taxon":  ""
                                                                                                                               },
                                                                                                                     "locale":  "en",
                                                                                                                     "phase":  "live",
                                                                                                                     "public_updated_at":  "2018-09-16T20:30:51Z",
                                                                                                                     "schema_name":  "taxon",
                                                                                                                     "title":  "Health and social care",
                                                                                                                     "web_url":  "https://www.gov.uk/health-and-social-care",
                                                                                                                     "withdrawn":  false
                                                                                                                 }
                                                                                                             ]
                                                                                       },
                                                                             "locale":  "en",
                                                                             "phase":  "live",
                                                                             "public_updated_at":  "2019-02-06T16:16:55Z",
                                                                             "schema_name":  "taxon",
                                                                             "title":  "Medicines, medical devices",
                                                                             "web_url":  "https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood",
                                                                             "withdrawn":  false
                                                                         }
                                                                     ]
                                               },
                                     "locale":  "en",
                                     "phase":  "live",
                                     "public_updated_at":  "2018-08-22T12:56:19Z",
                                     "schema_name":  "taxon",
                                     "title":  "Clinical trials and investigations",
                                     "web_url":  "https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood-clinical-trials-investigations",
                                     "withdrawn":  false
                                 },
                                 {
                                     "api_path":  "/api/content/health-and-social-care/public-health",
                                     "api_url":  "https://www.gov.uk/api/content/health-and-social-care/public-health",
                                     "base_path":  "/health-and-social-care/public-health",
                                     "content_id":  "d6a4884e-769d-4b81-8ba5-b64394362d92",
                                     "description":  "",
                                     "details":  {
                                                     "internal_name":  "Public health",
                                                     "notes_for_editors":  "",
                                                     "visible_to_departmental_editors":  false
                                                 },
                                     "document_type":  "taxon",
                                     "links":  {
                                                   "parent_taxons":  [
                                                                         {
                                                                             "api_path":  "/api/content/health-and-social-care",
                                                                             "api_url":  "https://www.gov.uk/api/content/health-and-social-care",
                                                                             "base_path":  "/health-and-social-care",
                                                                             "content_id":  "8124ead8-8ebc-4faf-88ad-dd5cbcc92ba8",
                                                                             "description":  "",
                                                                             "details":  {
                                                                                             "internal_name":  "Health and social care",
                                                                                             "notes_for_editors":  "",
                                                                                             "visible_to_departmental_editors":  true
                                                                                         },
                                                                             "document_type":  "taxon",
                                                                             "links":  {
                                                                                           "root_taxon":  [
                                                                                                              {
                                                                                                                  "api_path":  "/api/content/",
                                                                                                                  "api_url":  "https://www.gov.uk/api/content/",
                                                                                                                  "base_path":  "/",
                                                                                                                  "content_id":  "f3bbdec2-0e62-4520-a7fd-6ffd5d36e03a",
                                                                                                                  "document_type":  "homepage",
                                                                                                                  "links":  {

                                                                                                                            },
                                                                                                                  "locale":  "en",
                                                                                                                  "public_updated_at":  "2023-06-28T09:32:34Z",
                                                                                                                  "schema_name":  "homepage",
                                                                                                                  "title":  "GOV.UK homepage",
                                                                                                                  "web_url":  "https://www.gov.uk/",
                                                                                                                  "withdrawn":  false
                                                                                                              }
                                                                                                          ]
                                                                                       },
                                                                             "locale":  "en",
                                                                             "phase":  "live",
                                                                             "public_updated_at":  "2018-09-16T20:30:51Z",
                                                                             "schema_name":  "taxon",
                                                                             "title":  "Health and social care",
                                                                             "web_url":  "https://www.gov.uk/health-and-social-care",
                                                                             "withdrawn":  false
                                                                         }
                                                                     ]
                                               },
                                     "locale":  "en",
                                     "phase":  "live",
                                     "public_updated_at":  "2018-09-17T15:15:14Z",
                                     "schema_name":  "taxon",
                                     "title":  "Public health",
                                     "web_url":  "https://www.gov.uk/health-and-social-care/public-health",
                                     "withdrawn":  false
                                 }
                             ]
              },
    "locale":  "en",
    "phase":  "live",
    "public_updated_at":  "2024-08-27T11:43:37+01:00",
    "publishing_app":  "whitehall",
    "publishing_request_id":  "21-1728911417.642-10.13.21.82-2430",
    "publishing_scheduled_at":  "2024-03-28T10:00:00+00:00",
    "rendering_app":  "government-frontend",
    "scheduled_publishing_delay_seconds":  2,
    "schema_name":  "detailed_guide",
    "title":  "Clinical trials for medicines: apply for authorisation in the UK",
    "updated_at":  "2024-10-22T13:10:59+01:00",
    "withdrawn_notice":  {

                         }
}
